Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Total Non-Current Liabilities: 2013-2025

Historic Total Non-Current Liabilities for Theravance Biopharma (TBPH) over the last 11 years, with Sep 2025 value amounting to $182.5 million.

  • Theravance Biopharma's Total Non-Current Liabilities rose 10.27% to $182.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.5 million, marking a year-over-year increase of 10.27%. This contributed to the annual value of $176.7 million for FY2024, which is 97.45% up from last year.
  • Latest data reveals that Theravance Biopharma reported Total Non-Current Liabilities of $182.5 million as of Q3 2025, which was down 8.60% from $199.6 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year Total Non-Current Liabilities high stood at $746.3 million for Q1 2021, and its period low was $89.5 million during Q4 2023.
  • In the last 3 years, Theravance Biopharma's Total Non-Current Liabilities had a median value of $163.5 million in 2024 and averaged $163.0 million.
  • In the last 5 years, Theravance Biopharma's Total Non-Current Liabilities plummeted by 85.96% in 2022 and then skyrocketed by 97.45% in 2024.
  • Over the past 5 years, Theravance Biopharma's Total Non-Current Liabilities (Quarterly) stood at $638.4 million in 2021, then tumbled by 85.96% to $89.6 million in 2022, then fell by 0.11% to $89.5 million in 2023, then surged by 97.45% to $176.7 million in 2024, then climbed by 10.27% to $182.5 million in 2025.
  • Its Total Non-Current Liabilities was $182.5 million in Q3 2025, compared to $199.6 million in Q2 2025 and $176.3 million in Q1 2025.